Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) (NCT05097989) | Clinical Trial Compass
TerminatedPhase 2
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Stopped: Sponsor Decision.
United States, Argentina, Australia100 participantsStarted 2022-01-14
Plain-language summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams \[mg\]) in addition to background therapy consistent with the standard of care in adult participants (≥ 18 to ≤ 75 years of age) with either LN or IgAN. The study will consist of an up to 6-week Screening Period, a 26-week blinded Initial Evaluation Period, a 24-week blinded Extended Treatment Period, and an Open-label Extension (OLE) Period of up to 2 years.
Safety will be monitored throughout the study.
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Exclusion criteria
. ≥ 50% interstitial fibrosis and tubular atrophy
. ≥ 50% glomerular sclerosis
. ≥ 50% active crescent formation
. Cyclophosphamide ≤ 6 months prior to Screening
. CNIs ≤ 1 months prior to Screening
. A cumulative dose of intravenous (IV) methylprednisolone \> 3 g
. Mycophenolate mofetil \> 2 g/day (or equivalent) for ≥ 8 consecutive weeks prior to Screening
. Prednisone or prednisone equivalent ≥ 0.5 mg/kg/day for ≥ 8 consecutive weeks prior to Screening
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial was terminated before completing — does my doctor know why it was stopped, and what does that mean for the reliability of any safety or effectiveness data that was collected?
2Since this was a Phase 2 trial that is no longer recruiting, are there other active trials studying similar complement-pathway or proteinuria-focused treatments for lupus nephritis or IgAN that my doctor thinks might be worth looking into?
3The trial was measuring percentage change in proteinuria at 26 weeks — based on whatever results may have been reported, does my doctor think that approach to tracking kidney response is relevant to how they'd monitor my own condition?
4Given that this trial is terminated and not available to join, would my doctor recommend starting with an established standard-of-care treatment now, rather than waiting to see if a similar study opens up?
5Is my doctor aware of any published or preliminary findings from this ALXN2050 study that could inform decisions about my treatment, even though the trial itself is no longer active?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Both Cohorts: Percentage Change in Proteinuria From Baseline at Week 26